Companies
From start-ups to market leaders, access critical company intelligence on a global scale
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Experience what our solutions have to offer with free access to highlights of our data, insights and analysis.
From start-ups to market leaders, access critical company intelligence on a global scale
From industry deep dives to global trends, access authoritative research from our experts
Uncover your next opportunity with trusted data & insights that cut across industries
Discover the disruptive forces shaping tomorrow's world, today
Explore our diverse collection of unique datasets and find the advantage you need
Get clarity into the latest emerging themes with our reports
Despite being a market monopolized by generics, osteoporosis is expected to undergo substantial change between 2017 and 2027.
Osteoporosis is often referred to as a “silent” disease, because the loss of bone occurs progressively and there are often no symptoms until the first fracture occurs. Despite being a market dominated by generics, osteoporosis is expected to undergo substantial change in the forecast period. Our Biosimilars market report covers topics including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the osteoporosis therapeutics market.
Changes are already being seen in the osteoporosis space, with the recent launch of Radius Health’s Tymlos (abaloparatide) in the US in 2017. Anabolic agents will continue to revolutionize the market, with the arrival of a novel sclerostin inhibitor, Evenity (romosozumab), and teriparatide biosimilars. Competition is expected to increase, driving down high price tags and potentially boosting the use of these therapies up the treatment paradigm.
Poor diagnosis rates, badly perceived drug side effects, and low compliance rates will continue to prove major hurdles for growth over the next 10 years.